Benefits
Immune system modulation
Cat's claw POAs demonstrate immunomodulatory effects — stimulating phagocytosis, NK-cell activity, and lymphocyte proliferation in laboratory studies. In small human studies a standardized water-soluble extract raised white-blood-cell counts and slowed the decline of antibody levels after a pneumococcal vaccine, both surrogate immune markers rather than a measured drop in infections. Traditional use for recurrent infections has mechanistic support but no large controlled trials.
Joint tenderness studied in rheumatoid arthritis (add-on to standard therapy)
A small Phase II RCT in 40 rheumatoid arthritis patients already taking sulfasalazine or hydroxychloroquine found that freeze-dried cat's claw extract reduced the number of painful (tender) joints more than placebo over 24 weeks (a 53.2% vs 24.1% reduction, p=0.044). Reductions in swollen joints and the Ritchie index appeared only in the later open-label phase, not in the blinded comparison. The trial was small and has not been confirmed in a larger study.
Anti-inflammatory and antioxidant activity
Cat's claw inhibits TNF-α production, NF-κB activation, and COX-2 expression in laboratory studies, and demonstrates antioxidant activity through direct free radical scavenging. These mechanisms support the traditional anti-inflammatory applications in arthritis and infection.
DNA repair support
AC-11 (a water-soluble cat's claw extract, also called C-MED-100) increased repair of DNA strand breaks in rats, and in a small 8-week study of 12 healthy adults it reduced measured DNA damage and raised DNA repair after a laboratory hydrogen-peroxide challenge. This is a cell-level laboratory marker in a tiny group and has not been shown to slow aging or prevent any disease in people.
Mechanism of action
POA immunostimulation vs. TOA immunosuppression
Pentacyclic oxindole alkaloids (POAs) stimulate immune function via macrophage activation and lymphocyte proliferation. Tetracyclic oxindole alkaloids (TOAs) competitively antagonize POA immune-stimulating activity. High-quality POA-standardized extracts (with minimal TOAs) are required for consistent immune benefits — explains the inconsistent results seen with non-standardized products.
NF-κB and TNF-α inhibition
Cat's claw alkaloids and quinovic acid glycosides inhibit NF-κB nuclear translocation and reduce TNF-α production in macrophages and synovial cells — providing the anti-inflammatory mechanism relevant to rheumatoid arthritis and inflammatory conditions.
Nucleotide excision repair pathway enhancement
AC-11® extract enhances the cellular nucleotide excision repair (NER) pathway that removes UV-induced and chemically-damaged DNA bases. This DNA repair activity has been measured as a laboratory marker in animals and in one small human volunteer study; it has not been shown to prevent any disease or slow aging in people.
Clinical trials
Randomized, double-blind, placebo-controlled phase II trial of freeze-dried Uncaria tomentosa extract (60 mg/day, pentacyclic-oxindole-alkaloid chemotype) vs placebo in 40 patients with active rheumatoid arthritis on sulfasalazine or hydroxychloroquine. 24 weeks. (Mur et al. 2002, J Rheumatol)
40 RA patients on standard DMARDs. 24-week intervention.
In the 24-week blinded phase the cat's claw group had significantly fewer painful (tender) joints than placebo (a 53.2% vs 24.1% reduction, p=0.044). Reductions in swollen joints and the Ritchie index appeared only in the later 28-week open-label phase, when the former placebo group also took the extract, so those are not placebo-controlled results. Mechanism via NF-κB inhibition by pentacyclic oxindole alkaloids (POAs). Note: small phase II trial — has not been followed by larger phase III confirmation. Important: tetracyclic oxindole alkaloid (TOA) chemotype of cat's claw is functionally different (potentially antagonistic to POA effects) — TOA-free POA-standardized extracts should be specified.